1. Home
  2. IEP vs IMVT Comparison

IEP vs IMVT Comparison

Compare IEP & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Icahn Enterprises L.P.

IEP

Icahn Enterprises L.P.

HOLD

Current Price

$7.72

Market Cap

4.7B

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$24.50

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IEP
IMVT
Founded
1987
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
5.0B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
IEP
IMVT
Price
$7.72
$24.50
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$30.78
AVG Volume (30 Days)
986.4K
1.1M
Earning Date
05-06-2026
02-06-2026
Dividend Yield
25.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,658,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.08
$12.72
52 Week High
$9.99
$29.25

Technical Indicators

Market Signals
Indicator
IEP
IMVT
Relative Strength Index (RSI) 50.39 46.81
Support Level $7.55 $22.00
Resistance Level $8.29 $24.63
Average True Range (ATR) 0.16 1.25
MACD 0.01 0.08
Stochastic Oscillator 56.44 55.61

Price Performance

Historical Comparison
IEP
IMVT

About IEP Icahn Enterprises L.P.

Icahn Enterprises LP provides diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: